NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUNLENCA (lenacapavir sodium) is a first-in-class HIV-1 capsid inhibitor approved in December 2022 for treatment of multi-drug resistant HIV-1 infection. It is administered as a subcutaneous injection and represents a novel mechanism of action targeting viral capsid assembly. This small molecule addresses a significant unmet need in heavily treatment-experienced patients with limited remaining options.
Peak15.2 years to LOE
Early-stage commercial growth phase with opportunity to build market presence in a high-value niche indication with limited competition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SUNLENCA offers exposure to a first-in-class mechanism in a high-value specialty market with significant unmet need and limited competitive pressure. The role provides career advancement opportunity in infectious disease commercialization with strong patent protection extending visibility through 2041.
Brand ManagerMedical Science Liaison
Worked on SUNLENCA at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.